文献速递疼痛医学

新型免疫健全同基因头颈癌疼痛小鼠模型:不依赖IL-1信号

A Novel Syngeneic Immunocompetent Mouse Model of Head and Neck Cancer Pain Independent of Interleukin-1 Signaling.
PubMed 文献 · Anesth Analg · 2021-01-01

研究在免疫健全雄性C57BL/6小鼠右后肢植入HPV阳性口咽鳞癌模型,采用von Frey纤维和面部表情量表评估疼痛,检测IL-1β表达。结果显示肿瘤植入后迅速出现痛觉过敏和自发痛,脊髓与循环IL-1β显著升高,但阻断IL-1信号(鞘内注射IL-1ra或Il1r1基因敲除)不能缓解头颈癌疼痛。结论:头颈癌疼痛不依赖IL-1信号。

要点

  • 肿瘤植入后早期即出现痛觉过敏和自发痛,此时肿瘤体积尚不显著。
  • 肿瘤小鼠脊髓和循环IL-1β水平显著升高。
  • 鞘内IL-1ra或Il1r1基因敲除均不能缓解头颈癌疼痛。

核心结论

  • 头颈癌疼痛不依赖IL-1信号,挑战了疼痛源于组织压迫或IL-1信号的常见观点。

研究设计与样本

  • 在免疫健全雄性C57BL/6小鼠右后肢植入HPV阳性口咽鳞癌模型,采用von Frey纤维和面部表情量表评估疼痛,qPCR和ELISA检测IL-1β。

主要发现

  • 肿瘤细胞植入后痛觉过敏和自发痛迅速出现,此时肿瘤体积尚不显著。
  • 肿瘤小鼠脊髓和循环IL-1β水平显著升高。
  • 鞘内注射IL-1ra或Il1r1基因敲除均不缓解头颈癌疼痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pain is one of the first presenting symptoms in patients with head and neck cancer, who often develop chronic and debilitating pain as the disease progresses. Pain is also an important prognostic marker for survival. Unfortunately, patients rarely receive effective pain treatment due to our limited knowledge of the mechanisms underlying head and neck cancer pain (HNCP). Pain is often associated with neuroinflammation and particularly interleukin (IL)-1 signaling. The purpose of this study is to develop a novel syngeneic model of HNCP in immunocompetent mice to examine the contribution of IL-1 signaling. METHODS: Male C57BL/6 mice were injected with a murine model of human papillomavirus (HPV+)-induced oropharyngeal squamous cell carcinoma in their right hindlimb to induce tumor growth. Pain sensitivity was measured via von Frey filaments. Spontaneous pain was assessed via the facial grimace scale. IL-1β was measured by quantifying gene expression via quantitative polymerase chain reaction (qPCR) and enzyme-linked immunosorbent assay (ELISA). RESULTS: Pain hypersensitivity and spontaneous pain develop quickly after the implantation of tumor cells, a time when tumor volume is still insignificant. Spinal and circulating IL-1β levels are significantly elevated in tumor-bearing mice. Blocking IL-1 signaling either by intrathecal administration of interleukin-1 receptor antagonist (IL-1ra) or by genetic deletion (interleukin-1 receptor knockout [Il1r1-/-]) does not alleviate HNCP. CONCLUSIONS: We established the first syngeneic model of HNCP in immunocompetent mice. Unlike inflammatory or nerve-injured pain, HNCP is independent of IL-1 signaling. These findings challenge the common belief that pain results from tissue compression or IL-1 signaling in patients with head and neck cancer.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Heussner MJ, Folger JK, Dias C, et al. A Novel Syngeneic Immunocompetent Mouse Model of Head and Neck Cancer Pain Independent of Interleukin-1 Signaling. Anesth Analg. 2021. PMID: 33323783. doi:10.1213/ANE.0000000000005302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。